---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-014601"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:41:05.395197+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma FY2024 net rev $2.6M; Phase 3 CN trial on track; restructuring cuts spend $30-35M

## Summary
- XOLREMDI net product revenue $2.6M from May 2024 launch through YE; cost of revenue $0.8M.
- Net loss FY2024 $37.5M (incl. $105M PRV gain); cash $102.8M; pro-forma runway into 1H 2026.
- Phase 3 4WARD trial for chronic neutropenia activated at ~90% sites; full enrollment expected Q3/Q4 2025; top-line data 2H 2026.
- Protocol amendment: enroll only moderate/severe CN (ANC<1000); co-primary endpoint refined to uniform ANC increase ≥500 cells/µL.
- Strategic restructuring reduces annual spend by $30-35M; includes headcount reduction, closing Vienna facility, and right-sizing US team.

## SEC filing metadata
- accession: 0001628280-25-014601
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828025014601/0001628280-25-014601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828025014601/xfor-20250325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-014601
- JSON: https://secwatch.observer/filing/0001628280-25-014601.json
- Plain text: https://secwatch.observer/filing/0001628280-25-014601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.